RBC Cuts Insys Therapeutics (INSY) PT By 27%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Apollo to acquire easyJet for £5.7B in cash deal
- Nielsen to acquire DoubleVerify in merger deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Jefferies Cuts Price Target on Insys Therapeutics (INSY) Following Preliminary 1Q Subsys Revenues
April 12, 2016 7:57 AM EDTJefferies maintained a Buy rating on Insys Therapeutics (NASDAQ: INSY), and cut the price target to $17.00 (from $23.00), following the release of the company's preliminary estimated revenues from Subsys. INSY reported that Subsys Q1 revenues should be $61-62M vs consensus ($86M) forecasts. Many... More
INSYS Therapeutics' (INSY) Price Target Reduced to $28 at Piper Jaffray
April 11, 2016 1:36 PM EDTPiper Jaffray maintained an Overweight rating on INSYS Therapeutics (NASDAQ: INSY) and reduced its price target to $28.00 (from $46.00).
For an analyst ratings summary and ratings history on INSYS Therapeutics click here. For more ratings news on INSYS Therapeutics click here.
Shares of INSYS Therapeutics closed at $17.66 yesterday.
... MoreInsys Therapeutics (INSY) Offers Prelim. Q1 Subsys Revenue; Notes Drop in Volumes
April 11, 2016 6:51 AM EDTInsys Therapeutics, Inc. (Nasdaq: INSY) announced that its preliminary estimated revenues from Subsys® (fentanyl sublingual spray) for the first quarter of 2016 will be in the range of $61 million to $62 million. Estimated revenues for the quarter reflect a decline in demand, as Subsys... More
